Forest Not Holding Its Breath For Aerospan
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest does not expect a near-term approval for Aerospan (flunisolide), a non-CFC formulation of its asthma therapy Aerobid
You may also be interested in...
Forest’s Sigh Of Relief: Aerospan Is Approved
Forest receives approval on Jan. 27 for a non-CFC formulation of its asthma therapy Aerobid.
Forest’s Sigh Of Relief: Aerospan Is Approved
Forest receives approval on Jan. 27 for a non-CFC formulation of its asthma therapy Aerobid.
Advisory Committee To Decide If Azmacort, Alupent, Intal Remain "Essential" Drugs
FDA's Pulmonary–Allergy Drugs Advisory Committee will be asked at July 14 meeting whether these and other asthma products provide an otherwise unavailable important public health benefit. Drugs using chlorofluorocarbon propellants could be delisted from essential use category if closely related non-CFC alternatives exist, even though they are not the same moiety, FDA suggests.